SCHEMBL6205528

SCHEMBL6205528

CCc1csc(-c2cc(F)ccc2N)n1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 3/20 0.38
RAB9A P51151 2/20 0.37
NPC1 O15118 1/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
SREBF2 Q12772 1/20 0.36
CCNE2 O96020 1/20 0.35
CCNE1 P24864 1/20 0.35
CDK2 P24941 1/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MAPT P10636 1/20 0.34
PLAT P00750 1/20 0.34
CDK5 Q00535 1/20 0.34
CDK5R1 Q15078 1/20 0.34
DRD4 P21917 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6224446 0.82 TYR (0.40) KDM4ELMNARAB9ANPC1POLB
SCHEMBL15014149 0.81 MAPT (0.45) SMN1; SMN2KDM4ELMNARAB9ANPC1
SCHEMBL18015819 0.79 ALDH1A1 (0.53) KDM4ELMNAGAAALDH1A1HPGD
SCHEMBL6226222 0.79 ALDH1A1 (0.47) SMN1; SMN2KDM4ELMNARAB9ANPC1
SCHEMBL6204921 0.76 EIF4E (0.43) SMN1; SMN2KDM4ELMNARAB9AGAA
SCHEMBL2225013 0.76 LMNA (0.62) SMN1; SMN2KDM4ELMNARAB9ANPC1
SCHEMBL996557 0.75 SREBF2 (0.43) SMN1; SMN2LMNARAB9ANPC1POLB
SCHEMBL18924618 0.74 SMN1; SMN2 (0.68) SMN1; SMN2KDM4ELMNAPOLBALDH1A1
SCHEMBL996913 0.74 MPL (0.49) KDM4ELMNAPOLBALDH1A1L3MBTL1
SCHEMBL13745641 0.73 KCNH2 (0.39) KDM4ENPC1CCNE2CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050277676-A1 M3muscarinic acetylcholine receptor antagonists GLAXO GROUP LIMITED (GB) 2005-12-15 US disclosed
EP-1549278-A4 M sb 3 /sb MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LTD (GB) 2005-12-14 EP disclosed
EP-1549278-A2 M sb 3 /sb MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2005-07-06 EP disclosed
WO-2004012684-A2 M3MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2004-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277676-A1 M3muscarinic acetylcholine receptor antagonists CHRM3, CHRM2, CHRM5 SMN1; SMN2 2953/4885KDM4E 4337/4885LMNA 3315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.